Thermo Fisher Scientific announced the launch of the Applied Biosystems™ PowerFlex™ Thermal Cycler on April 16, 2026. The new instrument builds on the company’s legacy of Applied Biosystems technology and is engineered to deliver enhanced flexibility, precise thermal performance, and improved productivity for modern molecular biology laboratories.
The PowerFlex platform is designed to meet the growing demand for high‑throughput PCR workflows. It enables laboratories to run complex assays faster and more accurately, and it supports fully skirted plates to facilitate automation on shared instruments—addressing the time pressure that many labs face today.
The launch is part of Thermo Fisher’s strategy to expand its PCR portfolio and reinforce its one‑stop‑shop model for biopharma and academic customers. By adding the PowerFlex to its lineup, the company expects incremental revenue and recurring consumable sales, aligning with its focus on productivity improvements and market expansion in the life‑sciences sector.
Pawan Singh, vice president and general manager of molecular biology, said, “Today’s labs are being asked to run more complex PCR workflows, often across shared instruments and under increasing time pressure. That’s where traditional systems start to fall short.” He added, “With the PowerFlex Thermal Cycler, we’ve reimagined flexibility and performance together so researchers don’t have to choose between speed, accuracy and ease of use. We’ve also added support for fully skirted plates to enable lab automation.”
While no immediate financial impact is reported, the PowerFlex launch positions Thermo Fisher to capture a larger share of the life‑sciences instrumentation market and strengthen its competitive stance against other thermal cycler manufacturers. The addition complements recent acquisitions and product innovations, reinforcing the company’s broader strategy to maintain market leadership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.